Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method

The aim of the study was to develop a deep learning (DL) algorithm to evaluate the pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer.

[1]  A M Thompson,et al.  Neoadjuvant treatment of breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  G. Hortobagyi,et al.  Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Maryellen L. Giger,et al.  Comparison of breast DCE-MRI contrast time points for predicting response to neoadjuvant chemotherapy using deep convolutional neural network features with transfer learning , 2017, Medical Imaging.

[4]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Yan‐Lin Gu,et al.  Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta‐analysis , 2017, Clinical breast cancer.

[6]  Thierry Metens,et al.  Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy , 2016, European Radiology.

[7]  A. Madabhushi,et al.  Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI , 2017, Breast Cancer Research.

[8]  L. Irwig,et al.  Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis , 2015, BMC Cancer.

[9]  Qifeng Yang,et al.  Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. , 2011, European journal of cancer.

[10]  S. Loibl,et al.  Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. , 2008, Journal of the National Cancer Institute.

[11]  J. Wildberger,et al.  The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review , 2013, Insights into Imaging.

[12]  Zaiyi Liu,et al.  Radiomics of Multiparametric MRI for Pretreatment Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study , 2019, Clinical Cancer Research.

[13]  I. Alvarado-Cabrero,et al.  Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. , 2009, Annals of diagnostic pathology.

[14]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Yeon-Hee Park,et al.  Analysis of Factors that Influence the Accuracy of Magnetic Resonance Imaging for Predicting Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer , 2013, Annals of Surgical Oncology.

[16]  G. Hortobagyi,et al.  Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Andrew Janowczyk,et al.  A deep learning classifier for prediction of pathological complete response to neoadjuvant chemotherapy from baseline breast DCE-MRI , 2018, Medical Imaging.

[18]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[19]  L. Calvo,et al.  Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients , 2016, Radiology and oncology.

[20]  D. Berry,et al.  Research issues affecting preoperative systemic therapy for operable breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.